Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G

World News: . []

NEW HAVEN Conn Nov 14 2017 GLOBE NEWSWIRE -- NasdaqACHN today reported preliminary proof-of-concept results from group 1 of its ongoing Phase 2 open-label 14-day study of ACH-4471 for patients with C3 glomerulopathy C3G or immune com plex-me...

More news and information about Achillion Pharmaceuticals, Inc.

Published By:

Globe Newswire: 21:01 GMT Tuesday 14th November 2017

Published: .

Search for other references to "achillion" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers